1490 related articles for article (PubMed ID: 24267198)
21. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.
Shepherd J; Rogers G; Anderson R; Main C; Thompson-Coon J; Hartwell D; Liu Z; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(19):iii-iv, 1-360. PubMed ID: 18485271
[TBL] [Abstract][Full Text] [Related]
22. Anti-IgE for chronic asthma in adults and children.
Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
Cochrane Database Syst Rev; 2006 Apr; (2):CD003559. PubMed ID: 16625585
[TBL] [Abstract][Full Text] [Related]
23. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in children under the age of 12 years.
Main C; Shepherd J; Anderson R; Rogers G; Thompson-Coon J; Liu Z; Hartwell D; Loveman E; Green C; Pitt M; Stein K; Harris P; Frampton GK; Smith M; Takeda A; Price A; Welch K; Somerville M
Health Technol Assess; 2008 May; 12(20):1-174, iii-iv. PubMed ID: 18485272
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting.
Suzuki C; Lopes da Silva N; Kumar P; Pathak P; Ong SH
J Med Econ; 2017 Aug; 20(8):832-839. PubMed ID: 28532191
[TBL] [Abstract][Full Text] [Related]
25. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
Siergiejko Z; Świebocka E; Smith N; Peckitt C; Leo J; Peachey G; Maykut R
Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
[TBL] [Abstract][Full Text] [Related]
26. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
27. Interventions for autumn exacerbations of asthma in children.
Pike KC; Akhbari M; Kneale D; Harris KM
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012393. PubMed ID: 29518252
[TBL] [Abstract][Full Text] [Related]
28. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
[TBL] [Abstract][Full Text] [Related]
29. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
Padullés Zamora N; Comas Sugrañes D; Méndez Cabaleiro N; Figueras Suriol A; Jodar Masanes R
Farm Hosp; 2013; 37(5):399-405. PubMed ID: 24128103
[TBL] [Abstract][Full Text] [Related]
30. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
31. A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults.
Squires H; Poku E; Bermejo I; Cooper K; Stevens J; Hamilton J; Wong R; Denniston A; Pearce I; Quhill F
Health Technol Assess; 2017 Nov; 21(68):1-170. PubMed ID: 29183563
[TBL] [Abstract][Full Text] [Related]
32. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
[TBL] [Abstract][Full Text] [Related]
33. Anti-IgE for chronic asthma in adults and children.
Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
Cochrane Database Syst Rev; 2004; (3):CD003559. PubMed ID: 15266491
[TBL] [Abstract][Full Text] [Related]
34. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
[TBL] [Abstract][Full Text] [Related]
35. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
36. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study.
Barnes N; Menzies-Gow A; Mansur AH; Spencer D; Percival F; Radwan A; Niven R
J Asthma; 2013 Jun; 50(5):529-36. PubMed ID: 23574000
[TBL] [Abstract][Full Text] [Related]
38. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma.
Ni Chroinin M; Greenstone IR; Danish A; Magdolinos H; Masse V; Zhang X; Ducharme FM
Cochrane Database Syst Rev; 2005 Oct; (4):CD005535. PubMed ID: 16235410
[TBL] [Abstract][Full Text] [Related]
39. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
Braunstahl GJ; Chen CW; Maykut R; Georgiou P; Peachey G; Bruce J
Respir Med; 2013 Aug; 107(8):1141-51. PubMed ID: 23721684
[TBL] [Abstract][Full Text] [Related]
40. The role of omalizumab in the treatment of severe allergic asthma.
Chapman KR; Cartier A; Hébert J; McIvor RA; Schellenberg RR
Can Respir J; 2006; 13 Suppl B(Suppl B):1B-9B. PubMed ID: 16909166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
